Leap TherapeuticsNASDAQ: LPTX

CAMBRIDGE, Mass. , Nov. 13, 2024 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today reported financial results for the third quarter ended September 30, 2024.

Biotech stocks are some of my favorite stocks to watch and invest in for a couple of reasons.

Leap Therapeutics (LPTX) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.

30% ORR and 93% DCR across heterogenous second-line CRC patients treated with DKN-01 plus bevacizumab and chemotherapy Subgroup analysis reveals greatest benefit in left-sided tumors, particularly rectal and rectosigmoid patients with 46% ORR, 100% DCR, and preliminary median PFS of 9.4 months. Leap to host conference call to report additional clinical data including further subgroup analyses on Tuesday, January 23, 2024 at 8:30 a.m.

19.5 months median OS in the overall first-line patient population, exceeding current benchmarks Long-term follow-up identifies additional patient with partial response, resulting in 73% ORR in overall mITT population, including 86% ORR in PD-L1-low patients CAMBRIDGE, Mass. , May 25, 2023 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq: LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced the Company will be presenting new long-term follow-up data in first-line patients with advanced gastric or gastroesophageal junction adenocarcinoma (GEA) from Part A of the DisTinGuish study, a Phase 2 clinical trial evaluating Leap's anti-Dickkopf-1 (DKK1) antibody, DKN-01, in combination with BeiGene's tislelizumab and chemotherapy, at the upcoming 2023 American Society of Clinical Oncology (ASCO) Annual Meeting taking place in Chicago, IL on June 2-6, 2023.